# GLP-1 drugs to reverse endometrial precancer in women with obesity

Source: https://onco.cc/ideas/idea-prev-glp1-endometrial-hyperplasia/  
OnCo record `idea-prev-glp1-endometrial-hyperplasia` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Womb precancer in women with obesity is usually treated with a hormone coil or hysterectomy. Weight-loss drugs might reverse it and protect fertility.

## Summary

Womb precancer in women with obesity is usually treated with a hormone coil or hysterectomy, so this idea tests whether adding a GLP-1 receptor agonist to the levonorgestrel intrauterine system reverses atypical endometrial hyperplasia and protects fertility. Obesity drives the condition and a substantial share of cases progress to cancer; weight loss after bariatric surgery reverses hyperplasia, and GLP-1 drugs offer a non-surgical route. The aim is more complete regression and less relapse than the intrauterine system alone. The test is a 300-woman RCT with histological regression at six months as the endpoint. At early-clinical maturity it addresses the bottleneck Prevention we already have is not deployed and links to chemoprevention and endometrial cancer.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Adding a GLP-1 receptor agonist increases complete regression from about 70% to at least 85% and halves relapse at two years.
- Rationale: Weight loss after bariatric surgery reverses hyperplasia; GLP-1 offers a non-surgical route.
- Proposed test: 300-woman RCT.
- Maturity: early-clinical
- Actor: research

## Sources

- Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018): https://doi.org/10.3322/caac.21440

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/)
- fronts: [Prevention & Risk](https://onco.cc/fronts/prevention/)
- technologies: [Chemoprevention & risk-reducing surgery](https://onco.cc/technologies/chemoprevention/), [GLP-1 receptor agonists and obesity-related cancer risk](https://onco.cc/technologies/glp1-agonists-cancer-risk/)
- bottlenecks: [Prevention we already have is not deployed](https://onco.cc/bottlenecks/b-prevention-adoption/)
- key papers: [Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States](https://onco.cc/key-papers/paper-islami-ca-cancer-j-clin/)
- roadmaps: [Diet, exercise and lifestyle roadmap: causes established → interventions that disappointed → exercise proven as treatment](https://onco.cc/roadmaps/nutrition-lifestyle-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/idea-prev-glp1-endometrial-hyperplasia.json